Literature DB >> 12010764

Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery.

Demet Akin1, H Ongun Onaran, Hakan Gurdal.   

Abstract

1. Sumatriptan or eletriptan produced vasocontraction in common carotid artery (CCA) by stimulating 5HT(1B) receptors (see also Akin & Gurdal, this issue). 2. Naratriptan as a 5HT(1B/D) agonist, was unable to produce vasocontraction in this artery, but inhibited the vasocontractile response induced by sumatriptan or eletriptan. 3. All these agonists inhibited forskolin-stimulated cyclic AMP production with comparable potencies and maximal responses. This inhibition was mediated by 5HT(1B) receptors: 5HT(1B) antagonist SB216641 (1 microM) completeley antagonized sumatriptan-, eletriptan- or naratriptan-induced cyclic AMP inhibition, but 5HT(1D) antagonist BRL15572 (1 microM) did not affect this response. 4. Naratriptan-induced stimulation of 5-HT(1B) receptors resulted only in adenylate cyclase inhibition, whereas stimulation of these receptors by sumatriptan or eletriptan produced vasocontraction as well. Hence, we concluded that the 5HT(1B)-mediated inhibition of adenylate cyclase was not a sufficient condition to couple the receptor stimulation to vasocontraction. 5. We discussed agonist-induced trafficking as a plausible mechanism for the observed phenomenon.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010764      PMCID: PMC1573348          DOI: 10.1038/sj.bjp.0704710

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Allosteric equilibrium model explains steady-state coupling of beta-adrenergic receptors to adenylate cyclase in turkey erythrocyte membranes.

Authors:  O Ugur; H O Onaran
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

2.  SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.

Authors:  G W Price; M J Burton; L J Collin; M Duckworth; L Gaster; M Göthert; B J Jones; C Roberts; J M Watson; D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-09       Impact factor: 3.000

Review 3.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

Review 4.  The classification of drugs and drug receptors in isolated tissues.

Authors:  T P Kenakin
Journal:  Pharmacol Rev       Date:  1984-09       Impact factor: 25.468

5.  Evidence for 5-HT1D beta but not 5-HT1D alpha receptor subtype expression in canine large coronary arteries and saphenous vein.

Authors:  F Sgard; C Faure; D Graham
Journal:  Cardiovasc Res       Date:  1996-05       Impact factor: 10.787

6.  Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935.

Authors:  P J Pauwels; F C Colpaert
Journal:  Eur J Pharmacol       Date:  1996-04-04       Impact factor: 4.432

7.  Recombinant saphenous vein 5-HT1B receptors of the rabbit: comparative pharmacology with human 5-HT1B receptors.

Authors:  T Wurch; C Palmier; F C Colpaert; P J Pauwels
Journal:  Br J Pharmacol       Date:  1997-01       Impact factor: 8.739

8.  Dual coupling of cloned human 5-hydroxytryptamine1D alpha and 5-hydroxytryptamine1D beta receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis toxin-sensitive G protein(s).

Authors:  J M Zgombick; L A Borden; T L Cochran; S A Kucharewicz; R L Weinshank; T A Branchek
Journal:  Mol Pharmacol       Date:  1993-09       Impact factor: 4.436

Review 9.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

10.  Expression of serotonin receptor mRNAs in blood vessels.

Authors:  C Ullmer; K Schmuck; H O Kalkman; H Lübbert
Journal:  FEBS Lett       Date:  1995-08-21       Impact factor: 4.124

View more
  1 in total

Review 1.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.